By flow cytometry and an extensive set of markers, we characterized leukemic cells from the blood and bone marrow of 68 symptomatic patients with hairy cell leukemia (HCL). Hairy cells identified in the large cell gate always expressed CDl9, CD20, HLA-DR. CD#RA, and B-ly 7. Other markers were occasionally expressed, such as CD38, CD45R0, CD23, CD15, CD4 CD5, and CD10 (expressed on more than 20% of the hairy cells in 44%. 25%. 2196, l8%, 12%. IO%, and 5% of evaluated cases, respectively). During treatment with 2-chlorodeoxyadenosine (CdA), the median lymphocyte counts decreased from 2,0001pL t o 3OO/pL. Flow cytometry was repeated at the nadir (n = 24) of lymphocyte counts, at 3 months (n = 46). at 6 months (n = 50). at 1 year (n = 39).
result in an even higher complete remission rate8'9.'6"x from a single week of therapy, either as a continuous intravenous infusion' or as daily subcutaneous injections.'' Among patients with pretreatment anemia, treatment is frequently complicated by neutropenic fever, '8.20 .Z1 either during the treatment course, which might be caused by rapid tumor cell lysis, or during the following weeks, which may be caused by opportunistic
To assess the phenotypic variability of hairy cells, and to evaluate the long-term effects of CdA on immune cells we used flow cytometry analyses with an extensive set of markers on blood and bone marrow cells in patients with active disease before and after CdA treatment.
PATIENTS AND METHODS
A total of 75 patients, 63 men and 12 women, with symptomatic HCL were studied, some of whom are previously reported.'s'20 Diagnosis was made through morphology with cytochemistry on repeated bone marrow aspirations and biopsy specimens. Thirty-four patients were previously untreated, and 41 had received prior treatment, 1 of them (patient JJ in Juliusson and Liliemark") including deoxycoformycin. Their mean age was 53 years (range, 29 to 75), and sampling of blood and bone marrow was performed with a median of 10 months from diagnosis. All patients were subsequently treated with CdA for 7 days, either as a continuous infusion of 0.085 mg/ ,,/dla or as daily subcutaneous injections of 3.4 rnglm'.'' These treatment schedules give the same concentrations of CdA nucleotides in leukemic cells22~2' (and Liliemark and Juliusson, manuscript in preparation) and similar clinical results.'' Peripheral blood counts were in most cases evaluated once or twice weekly during the first months after CdA treatment, and such data were available from 70 patients. Blood and bone marrow sampling for flow cytometry was repeated 3 months (n = 46), 6 months (n = 50). 1 year (n = 39). and 2 years (n = 12) after C M treatment. Thus, flow cytometry was performed on at least 4 occasions in most patients. In addition, blood for flow cytometry was sampled from some patients at lymphocyte nadir 1 week (n = 24) and 1 month from the start of C M treatment (n = 7). Ten patients received a second course of C M because of residual disease. Approval was obtained from the Institutional Review Board. Informed consent was provided according to the Declaration of Helsinki. 
RESULTS
Phenotype of hairy cells. The hairy cell phenotype could be assessed in 68 patients, either by analysis of the peripheral blood, bone marrow cells, or both ( Table 2 ). The median percentage of hairy cells in the large cell gate (Fig l) , as assessed by the CD20 positivity, was 90% (Fig 2) , and contained less than 5% monocytes. In three quarters of the patients there were more than 80% hairy cells in the gate, enabling the identification of aberrant expression of cell markers without double fluorescent staining, which, however, confirmed expression of certain cellular markers in many patients.
Almost all hairy cells expressed CD19, CD20, CD25, HLA-DR, and CD45RA (Fig 2) . A median of two-thirds of the cells expressed B-ly 7, and 8% of the patients had less than 20% B-ly 7-positive cells in the large cell gate. However, unusual expression of one or another marker was found in a majority of the cases (Table 3) . CD38, CD45R0, CD15, CD4, CD10, CD5 (Fig lb, plot C) , andlor CD23 were occasionally expressed on a majority of the hairy cells (Fig 2) . Also, CD25 and B-ly 7 were expressed only on a minority of the hairy cells in some patients. Initial changes a f e r treatment in dejned lymphocyte subsets. The lymphocyte gate of all samples contained less than 3% monocytes. Through the flow cytometry data achieved at lymphocyte count nadir we were able to determine the early kinetics of the CdA effects on different cell populations. Figure 4 shows the median percentage of cell subsets for 24 patients with nadir data available. The variation of the percentages in between patients was great, with less change in between measurements on different time points in individual patients (Fig 4) ; however, the changes were in the same direction in most patients. CD20+, CD8+ cells and NK cells were found in lower percentages at nadir than pretreatment, whereas the percentage of CD4+ cells were higher at nadir (differences significant when analyzed with either the t-test for paired samples or the Wilcoxon matched pairs test, Fig 4) . This indicates a slower decrease of CD4+ cells after CdA treatment than of the other cell populations. Correspondingly, in these 24 cases, the CD4/ CD8 ratio was significantly higher at nadir as compared with were found at subsequent time points as compared with nadir. Thus, the recovery from nadir was more rapid for NK cells and CD8' cells than for CD4+ cells and B cells, leading to a slowly but progressively decreasing CD4/CD8 ratio.
The absolute cell counts for various lymphoid cell subsets in relation to treatment are shown in Fig 5 and Table 4 . The median CD4' cell count was close to the normal range 1 year after the s m of CdA treatment, whereas the CD8+ cells normalized within 3 months. Of interest was that several specific B-and T-cell subsets had a quicker recovery than the overall B-and T-cell populations (Fig 5 and Table  4 ). The results were not different whether the patients had received CdA intravenously or subcutaneously (Kolmogornov Smimov nonparametric two-sample test. These values were significantly different from the baseline value by nonparametric statistics at 3, 6, and 12 months (Wilcoxon matched pairs test: P = .036, P = .0007, and P = .0017, respectively). Sixteen of 36 evaluable patients (44%) with less than 2% CDIO' cells of the pretreatment bone marrow lymphoid cells showed an increase to 5% or more at follow-up, with the kinetics shown in Fig 6. 
DISCUSSION
By flow cytometry with an extensive set of antibodies and double fluorescent staining, we have analyzed the phenotype of hairy cells from 68 patients with symptomatic disease. Furthermore, by frequent samplings from 50 patients after CdA treatment, we were able to determine the selective toxicity of this agent towards specific lymphoid cell subsets and their subsequent recovery. The phenotype of hairy cells is known to be CD19', CD20', CD22', CD25', B-ly 7', CD5-, and CD1 lc+.2.24.30 We also found that HLA-DR and CD45RA"' were consistantly expressed. In addition, hairy cells from a large proportion of the patients express other markers. CD1 IC is a monocyte marker that is typically found on hairy cells,"* but we also frequently found expression of CD15, another monocyte marker. Expression of CD4, the T-helpedinducer cell marker; CDIO, the common acute lymphoid leukemia antigen indicating early B-cell differentiation; and CD5, the Tcell marker typically found on B-cell chronic lymphocytic leukemia, were also verified by double fluorescent staining in significant numbers of patients. Thus, hairy cells commonly have aberrant phenotypes, with simultaneous expression of divergent markers of differentiation and cell lineage. Hairy cells from some patients also lacked expression of characteristic markers, such as CD2S3 and B-ly 7, at least in a proportion of the leukemic cells. The identification of minor subpopulations of hairy cells with aberrant phenotype mostly requires double fluorescent staining using the relevant combination of markers. Because far from all combinations were possible to determine, it is likely that aberrant expression is more common than we have been able to document. Cells from the disease entity called HCL variant4 lack CD25, but were recently found to express IL-2 receptor p chains.33
Our phenotype data rather indicate a spectrum of HCL variants than one typical variant entity. We did not find any correlation between the phenotype and the response to treatment (data not shown). CdA gives a much higher complete remission rate in HCL than interferon,8 and thus divergent response to CdA treatment according to any marker is difficult to assess.
There is limited previous data available on the immune 
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with CD4, CD8, and CD20, and NK cells in the lym- .. suppression caused by CdA ~e a t m e n t . " . '~.~' .~~~~' An early decrease in both CD4 ' and CD8' cells after treatment is found, and a slow recovery during the subsequent year was indicated from sporadic observations. From the combined data collected at the Scripp's clinic and the MD Anderson Cancer Center, it was concluded that the mean CD4 count nadir was 272/yL and occurred 4 to 6 months from treatment." This discrepancy to our data probably reflects the lack of systematic phenotype analyses in the early posttreatment phase in the US studies.
In the present study, we have characterized the degree and the kinetics of both the decrease and the recovery as regards several of the lymphocyte subsets. During CdA treatment, there is a rapid decrease of most of the studied lymphocyte subsets, but CDS, CD20, and NK-cell subsets decreased significantly more than CD4 cells. The median CD8 cell count at nadir was well below lOO/yL, whereas the corresponding CD4 count was 128/yL. The recovery from nadir was quicker for CD8 cells, NK cells, and T-cell receptor yS' cells, and the median blood counts of these subsets were all normal within 3 months, whereas CD4+ cells required 1 year or more for normalization, leading to a slowly but progres- sively decreasing CD4/CD8 ratio. Of specific interest was that the activated HLA-DR+ subset of CD4+ cells was fully normalized already at 3 months after CdA treatment, as were the NK cells, the CD5+ B cells, and the CD45RNCD45RO cells (Fig 5 and Table 4 ). Furthermore, the absolute numbers of HLA-DR+ subset of CD8+ cells decreased within the normal range, and often recovered with an overshoot. We have previously documented post-CdA-treatment overshoot of other leucocytes, such as monocytes and eosinophils." However, CD4'/CD45RA' cell counts had a late nadir, almost within the normal range.
CdA-treated HCL patients are at great risk for neutropenic fever if they have pretreatment pancytopenia, especially anemia.'' However, no infections present later than 1 month from CdA treatment, despite continuing low levels of several lymphocyte subsets during 6 to 12 months. The activated CD38' and HLA-DR' T-cell subsets, the CD5' B cells, and the NK cells that rapidly normalize after CdA-treatment might thus, in combination with the recovering neutrophils," be an adequate first-line defense.
As regards the B cells, the CD23+ B cells also recovered promptly from 3 to 6 months, whereas the total CD20' cell population required 1 year for normalization of the cell counts. Increased relative numbers of B-cell progenitors, ie, CDIO' cells, appeared in the bone marrow after treatment in 16 of 36 patients (Fig 6) . We have seen the similar phenomenon during successful CdA treatment of chronic lymphocytic leukemia.36 It is unlikely that these CDlO+ B cells represented leukemia cells, because they were seen primarily in patients with leukemia cell clones laclung CDIO, and in those achieving complete remission. There was a normalization of the percentage of CD10' cells with longer follow-up without further treatment. This could not be caused by a selective depletion of bone marrow subsets other than CD10' cells, according to bone marrow cellularity, morphology, and flow cytometry data (not shown). It is more likely that we observed a regeneration of normal B cells, enabled by an effective and brief cytotoxic treatment. Such B-cell regeneration might be a common but hitherto unknown phenomenon after successful chemotherapy, because CDIO' cells were very rare in the peripheral blood, and systematic phenotype studies on bone marrow cells have not been performed previously. However, CDlO+ bone marrow cells are described to appear after autologous bone marrow tran~plantation.'~ B-cell regeneration is probably also mirrored by the recent finding that CdA3x,39 and fl~darabine,''',~' in contrast to conventional chem~therapy,".~' may increase polyclonal gammaglobulin levels in patients with chronic lymphocytic leukemia. However, we cannot exclude the possibility that CdA has a direct stimulatory effect on normal B-cell progenitors, which, if it would occur with a lower dose range than the cytotoxic effect, could be exploited in B-cell dysfunction states.
As yet, no studies have attempted to optimize CdA scheduling. Monitoring of the immune cells by flow cytometry and the time to recovery from cytopenias after various treatment schedules might facilitate the establishment of an optimal regime without the need for large-scale clinical trials. The immunosuppressive effects of CdA may also be possible to use in nonmalignant disorders, such as rheumatoid arthritis and multiple ~clerosis.~ How cytometry monitoring might then again prove useful when establishing adequate dosing and scheduling of the treatment.
Cytopenias and infections are the major side effects for most agents used for treatment of malignancy, and have to be considered when selecting treatment. DCF is highly effective therapy for hairy cell leukemia, but has to be administered in repeated doses. A long-standing suppression of CD4+ cells has, in disorders other than HCL, been associated with severe opportunistic infections, such as candida pneumonitis, central nervous system infections with Listeria and Aspergillus, and disseminated herpes zoster.I5 In Steis et al's of dCF in HCL, the median nadir of CD4+ cell counts was 54/j~L,4~ and in other studies the median CD4 nadir was between 70 and 1 5 5 / j~L . '~. '~*~.~~ Normalization of CD4 counts and CD8 counts may occur a median of 23 and 15 months after the start of dCF treatment, respectively." Because the T-cell counts remain low during the full duration of dCF treatment,I3 the immune depression is likely to be shorter after treatment with CdA than with dCF. However, the immune suppression is likely to be dose-related for both dCF and CdA, and the lowest effective dose for HCL has not been established for either of the drugs.
Fludarabine is not recommendable for HCL, but it is an important nucleoside analog for the treatment of other lymphoid neoplasms' and is structurally closely related to CdA.3S Fludarabine also produces a severe depletion of CD4+ cells when administered in repeated courses to patients with chronic lymphocytic leukemia and lymph0ma.4~.~~,~'
Interferon, the established first-line treatment of HCL;' does not induce T-cell depletion to a degree similar to that of the nucleoside analogues. However, HCL by itself causes immunologic impairment, the complete response rate to interferon is considerably lowe? than for CdA, and the improvement is also slower." Thus, patients may die from opportunistic infections during induction treatment with interfer0n.4~~~~
In conclusion, CdA is highly cytotoxic towards all lymphoid subsets during treatment. These short-term effects cause a significant acute morbidity through neutropenic in- For personal use only. on August 30, 2017 . by guest www.bloodjournal.org From 3680 JULIUSSON, LENKEI, AND LlLlEMARK fections.'8 Thus, the evaluation of other dose schedules, facilitated by the use of subcutaneous administration'9.21 and flow cytometry monitoring, should be performed. Prolonged immunosuppression from CdA is not a significant clinical problem in HCL. Partial regeneration of several normal subsets occurs rapidly, whereas the full recovery may be delayed, although this recovery is quicker than after dCF treatment. Drug-induced immune suppression will be a major concern when choosing between the available treatment options for lymphoproliferative disorders," and this has to be considered in comparative trials in the near future.
